111 Inc (YI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of 111 Inc $6.70, price $3.71, upside +80.6%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch 111 Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.56 – $92.20 · fair‑value band $4.29 – $10.61 · the $3.71 price screens below the $6.70 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow 111 in your weekly email
Every Wednesday you see whether 111 is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B.
Show more
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides drugs, nutritional supplements, medical supplies and devices, personal care, and baby products. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool, as well as online consultation, e-prescription, and data services. Further, its pharmacies provide drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and marketplace sellers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Stock analysis
111 Inc (YI) currently trades at $3.71, while our model-based Fair Value estimate is $6.70, implying the stock looks roughly 44.6% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $9.80 per share, and 6 of the 8 models we run sit above the $3.71 price.
Bear case: the Multiples group reads lowest at $1.31, and 2 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: $4.29 (bear) to $10.61 (bull), the price of $3.71 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
111 Inc reported revenue of 12.2B CNY in FY2025 versus 12.4B CNY in FY2021, a compound −0.4%/yr. Reported net income was −16.8M CNY in FY2025.
Key figures
Market cap $35.3M · EPS (TTM) $−7.62 · Net margin −0.1% · Return on equity −14.8% · Return on assets (EBIT) −8.6% · Operating margin −0.9% · Revenue (TTM) 11.4B CNY · Revenue growth (YoY) −33.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 56% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 81%, YI screens cheaper than that median.
Fair Value models
Bear $4.29Fair Value $6.70Bull $10.61
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.8% (2020) → −0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside+81% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−1% · Bottom 25%
Net margin (TTM)−1% · Bottom 25%
Operating margin (TTM)−1% · Bottom 25%
Growth and dividend
Revenue growth−33% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/FCF0.3× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 42
FUTURE (revenue growth)0· sector 17
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 59
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "111 Inc Fair Value". https://www.fairvalue-calculator.com/stock/YI
Frequently asked questions
Is 111 Inc (YI) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $6.70 versus a price of $3.71, about +81% upside (undervalued).
What is the fair value of YI?
Our model-based fair value for 111 Inc is $6.70 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.71.
What is the quality score of YI?
111 Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 111 Inc (YI)?
Our model-based price target is the fair value of $6.70 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario $4.29, optimistic scenario $10.61. It is a calculation from audited fundamentals, not an analyst target.
What is the 111 Inc stock forecast for 2026?
Our models put fair value at $6.70, about +81% upside versus a price of $3.71 (undervalued). Cautious scenario $4.29, optimistic scenario $10.61. The calculation is refreshed regularly with new filings.
What is the revenue of 111 Inc (YI)?
111 Inc reported trailing-twelve-month revenue of about 11.4B CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of 111 Inc (YI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 111 Inc it is $6.70 per share (as of Sep 24, 2026), against a price of $3.71. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is 111 Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, YI trades below its calculated fair value: price $3.71, fair value $6.70, a gap of about +81% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YI?
No. The price is what the market pays today ($3.71); the fair value is what the company's own numbers justify ($6.70). For 111 Inc the two are $2.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is 111 Inc worth?
The market values 111 Inc at about $35.3M (market capitalisation, as of Sep 24, 2026). Per share that is $3.71; our models calculate a fair value of $6.70 per share.
What do the bullish and bearish scenarios say about YI?
Our models span a range for 111 Inc: cautious scenario $4.29, base $6.70, optimistic $10.61 per share (as of Sep 24, 2026, price $3.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 111 Inc (YI)?
Balance-sheet figures for 111 Inc (as of Sep 24, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is YI from its 52-week high?
111 Inc trades at $3.71, about 56% below its 52-week high of $8.38 and 45% above the low of $2.56 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $6.70 is for.
Which stocks are comparable to 111 Inc?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 111 Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.71, calculated fair value $6.70 (+81%), Quality Score 58/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YI calculated?
We run 111 Inc through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.70, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. 111 Inc currently trades 81 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 111 Inc (YI)?
The closing price on Sep 23, 2026 was $3.71. Our model-based fair value is $6.70, about +81% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 111 Inc right now?
The price is below even our cautious bear case ($4.29). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($4.29 to $10.61) leaves room in how you read the outcome.
Key figures of 111 Inc
How large is the market capitalisation of 111 Inc (YI)?
The market capitalisation of 111 Inc is $35.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of 111 Inc (YI)?
Earnings per share at 111 Inc are $−7.62. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of 111 Inc (YI)?
The net margin of 111 Inc is −0.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of 111 Inc (YI)?
The return on equity (ROE) of 111 Inc is −14.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 111 Inc (YI)?
On an EBIT basis the return on assets of 111 Inc is −8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 111 Inc (YI)?
The operating margin of 111 Inc is −0.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 111 Inc (YI)?
Revenue at 111 Inc is growing −33.1% versus a year earlier (3y avg −3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 111 Inc (YI) generate?
The free cash flow of 111 Inc is 115M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does 111 Inc (YI) hold?
111 Inc holds more cash than debt, 344M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch 111 Inc in the live analysis
One click puts 111 Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026